Correlation Between Enveric Biosciences and Leap Therapeutics

Can any of the company-specific risk be diversified away by investing in both Enveric Biosciences and Leap Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enveric Biosciences and Leap Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Enveric Biosciences and Leap Therapeutics, you can compare the effects of market volatilities on Enveric Biosciences and Leap Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enveric Biosciences with a short position of Leap Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enveric Biosciences and Leap Therapeutics.

Diversification Opportunities for Enveric Biosciences and Leap Therapeutics

0.43

Correlation Coefficient

Enveric Biosciences  Leap Therapeutics

Very weak diversification

The 3 months correlation between Enveric and Leap is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding Enveric Biosciences and Leap Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Leap Therapeutics and Enveric Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enveric Biosciences are associated (or correlated) with Leap Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Leap Therapeutics has no effect on the direction of Enveric Biosciences i.e., Enveric Biosciences and Leap Therapeutics go up and down completely randomly.

Pair Corralation between Enveric Biosciences and Leap Therapeutics

Given the investment horizon of 90 days Enveric Biosciences is expected to under-perform the Leap Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Enveric Biosciences is 1.12 times less risky than Leap Therapeutics. The stock trades about -0.12 of its potential returns per unit of risk. The Leap Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  286.00  in Leap Therapeutics on August 31, 2024 and sell it today you would earn a total of  9.00  from holding Leap Therapeutics or generate 3.15% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Enveric Biosciences  vs.  Leap Therapeutics

Enveric Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Enveric Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Leap Therapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Leap Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Leap Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pair Trading with Enveric Biosciences and Leap Therapeutics

The main advantage of trading using opposite Enveric Biosciences and Leap Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enveric Biosciences position performs unexpectedly, Leap Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Leap Therapeutics will offset losses from the drop in Leap Therapeutics' long position.

The idea behind Enveric Biosciences and Leap Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.